TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05819294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Agitated Pleural Fluid Thoracentesis
Description: Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
Study: NCT06152978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
Study: NCT04961541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICC Vaccine
Description: Intramuscular (deltoid) injections of in-clinic mix of various doses of qNIV2, SARS-CoV-2 rS, and 50 μg Matrix-M1 Adjuvant (ICC Vaccine) on Day 0 and Day 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant
Description: Intramuscular (deltoid) injections of 60 μg qNIV Nanoparticle Vaccine2 in-clinic mixed with 75 μg Matrix-M1 Adjuvant on Days 0, Day 56, and an additional dose on Day 70.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant
Description: Intramuscular (deltoid) injections of 5 μg SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with 50 μg Matrix-M1 Adjuvant on Days 0 and Day 56.
Study: NCT04992065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 15 mg
Description: 15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 40 mg
Description: 40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo I A (for NNC0385-0434 A 15 mg)
Description: Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 A 100 mg
Description: 100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo I A (for NNC0385-0434 A 40 mg)
Description: Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo II A (for NNC0385-0434 A 100 mg)
Description: Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab 140 mg/mL, Repatha®
Description: Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL
Study: NCT06367686

Intervention type: DEVICE
Intervention: IscAlert sensor
Description: Insertion of an IscAlert sensor at the nasal mucosa

Intervention type: DEVICE
Intervention: IscAlert sensor
Description: Insertion of an IscAlert sensor at the nasal mucosa

Intervention type: DEVICE
Intervention: IscAlert sensor
Description: Insertion of an IscAlert sensor at the nasal mucosa

Intervention type: DEVICE
Intervention: IscAlert sensor
Description: Insertion of an IscAlert sensor at the nasal mucosa
Study: NCT05872997

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sensory Motor Training
Description: Mobilization With Movement Along With Sensory Motor Training
Study: NCT05467332

Intervention type: DEVICE
Intervention: HIGH FLOW NASAL OXYGEN
Description: BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES.
Study: NCT06233201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product
Description: Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
Study: NCT05352698

Intervention type: DIAGNOSTIC_TEST
Intervention: NT ProBNP (Roche)
Description: This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
Study: NCT04982328

Intervention type: DIAGNOSTIC_TEST
Intervention: Th17 cytokine profile
Description: Screening for the components of metabolic syndrome

Intervention type: DIAGNOSTIC_TEST
Intervention: Th17 cytokine profile
Description: Screening for the components of metabolic syndrome

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for the components of metabolic syndrome
Description: Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for the components of metabolic syndrome
Description: Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the degree of steatosis
Description: The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the degree of steatosis
Description: The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
Study: NCT05227560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary Therapies
Description: The emotional freedom technique was applied to the experimental group.
Study: NCT06157996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib and tislelizumab plus CapeOX chemotherapy
Description: Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tislelizumab plus CapeOX chemotherapy
Description: Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
Study: NCT05525052

Intervention type: OTHER
Intervention: Trans-Facet fixation
Description: Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
Study: NCT00236990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentosan polysulfate sodium
Study: NCT04316611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Description: Direct intravenous injection (IVD) 20 mmol potassium chloride
Study: NCT06157541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic cytomegalovirus-specific T cells
Description: Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic cytomegalovirus-specific T cells
Description: Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic cytomegalovirus-specific T cells
Description: Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
Study: NCT05955924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Oral nicotinamide (500 mg) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule twice daily
Study: NCT05954026

Intervention type: DEVICE
Group type: OTHER
Intervention: ExVent
Description: ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
Study: NCT06283797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6
Description: Participants will use Dexcom G6 for continuous glucose monitoring
Study: NCT06426121

Intervention type: DIAGNOSTIC_TEST
Intervention: test Aerobic/F Culture Vials
Description: an additional blood sample will be collected compared to clinical routine of blood culture, inoculated into the test culture vial, and compared with the blood culture results of the control vial collected from the same site and the same puncture point
Study: NCT06283797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAID questionnaires
Description: At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAID questionnaires
Description: At visits 3, 7 and 11, parents/guardians and patients aged between 8 and 17 will complete diabetes-related problem questionnaires (PAID-PR, PAID-Peds)
Study: NCT06003296

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Calcaneocuboid arthrodesis
Description: Calcaneocuboid arthrodesis in triple arthrodesis
Study: NCT06426121

Intervention type: DIAGNOSTIC_TEST
Intervention: control Aerobic/F Culture Vials
Description: according to the clinical routine of blood culture, this blood sample should be collected and inoculated into the control vial, and its culture result will be collected
Study: NCT05549609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XSTEM-VLU
Description: XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
Study: NCT05486676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.
Description: All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
Study: NCT05549609

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: CryoStor CS10 cryomedium
Study: NCT04684095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic patient report outcome
Description: ePRO was conducted every two weeks in addition to routine follow-up
Study: NCT06527248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate group
Description: Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
Study: NCT04693325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolonged normothermic machine perfusion
Description: First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted \[NMP1\]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) \[PNMP3\] and consequently 6 hours (n=6) \[PNMP6\].
Study: NCT05084274

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle program
Description: If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
Study: NCT05495906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccine
Description: Routine dosing form and dosage

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nonavalent HPV vaccine
Description: Routine dosing form and dosage
Study: NCT05025761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal protection package
Description: The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
Study: NCT06008457

Intervention type: DEVICE
Intervention: Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Description: The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.

Intervention type: DEVICE
Intervention: Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Description: The self-collected Labcorp COVID-19+Flu+RSV Test Home Collection Kit results as generated by the commercially available Labcorp Seasonal Respiratory Virus RT-PCR Test will be compared to the HCP-collected results as generated by Labcorp R\&D using the comparator assays.
Study: NCT03927131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV-IB
Description: Inactivated split-virion quadrivalent influenza vaccine
Study: NCT04742348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
Study: NCT06307522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001
Description: Patients will receive subcutaneous administration of MRG-001 at designated visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001
Description: Patients will receive subcutaneous administration of MRG-001 at designated visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001
Description: Patients will receive subcutaneous administration of MRG-001 at designated visits.
Study: NCT03783468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decrease of sedation doses and switch of ventilator settings
Description: tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
Study: NCT06311136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valence-Specific Ecological Momentary Intervention
Description: The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
Study: NCT06020066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TK Inhibitor
Description: Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist.
Study: NCT05254132

Intervention type: PROCEDURE
Intervention: Liquid biopsy
Description: Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
Study: NCT04930549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Patients receive dapagliflozin 10mg tablets once a day during 12 weeks